Drugs News and Research

RSS

First whole genome sequence of Parsi breast cancer woman

Avesthagen Limited has yet again established its position as a leader in the successful application of next gen technologies as it announces the completion of the first Parsi breast cancer whole genome sequence of a 74-year-old Parsi woman with a heritable form of breast cancer. The incidence of breast cancer in most populations is strongly linked to a genetic basis but little is known about the variants at the present time.

4 Jan 2011

New ATS guidelines for treating fungal infection in adult pulmonary and critical care patients

The American Thoracic Society has released a new official clinical policy statement on the treatment of fungal infections in adult pulmonary and critical care patients.

4 Jan 2011

Genocea announces close of $35 million Series B venture financing round

Genocea Biosciences Inc., a vaccine discovery and development company pioneering a new class of T cell-based vaccines, today announced that it has closed a $35 million Series B round of venture financing, with new investors Johnson & Johnson Development Corporation (JJDC), Skyline Ventures and MP Healthcare Venture Management, Inc. (MPH) joining existing investors Polaris Venture Partners, Lux Capital Management, SR One, Cycad Group, Auriga Partners and Morningside Ventures.

3 Jan 2011

General anaesthesia brings reversible coma and not sleep: Study

Anaesthesia has been one of the greatest gifts of science and use of general anaesthesia is a routine part of surgical operations at hospitals and medical facilities around the world. However precise biological mechanisms of the drugs’ effects on the brain are only now being analyzed. In a review article published this week in the New England Journal of Medicine, scientists have tried to analyze a range of disciplines, including neuroscience and sleep medicine to understand how anaesthesia actually works.

2 Jan 2011

Immunitor reports positive safety imm01 clinical trial against tuberculosis

Immune Network Ltd., advises that Immunitor has published data from the first half of the 120-patient imm01 clinical trial of its V5 immunomodulator product against tuberculosis, including difficult-to-treat forms of the disease.

30 Dec 2010

Health and Safety Watch tracks over 500 food and product advisories and recalls in 2010

This year Health and Safety Watch tracked more than 500 advisories and recalls issued for food and products in Canada. The events included everything from the recent Quaker Canada cereal bar recall due to the possible presence of peanuts, to big ticket items such as GE dishwashers recalled due to possible fire hazards.

30 Dec 2010

General anesthesia's similarities with and differences from sleep and coma

The use of general anesthesia is a routine part of surgical operations at hospitals and medical facilities around the world, but the precise biological mechanisms that underlie anesthetic drugs' effects on the brain and the body are only beginning to be understood. A review article in the December 30 New England Journal of Medicine brings together for the first time information from a range of disciplines, including neuroscience and sleep medicine, to lay the groundwork for more comprehensive investigations of processes underlying general anesthesia.

30 Dec 2010

Neuroscientists say that general anesthesia is a reversible coma

The brain under general anesthesia isn't "asleep" as surgery patients are often told -- it is placed into a state that is a reversible coma, according to three neuroscientists who have published an extensive review of general anesthesia, sleep and coma, in the Dec. 30 issue of The New England Journal of Medicine.

30 Dec 2010

Intellipharmaceutics granted extension of deadline to regain compliance with Nasdaq Listing Rule

Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel or generic controlled release and targeted release oral solid dosage drugs, today announced that the staff of the Nasdaq Stock Market has granted the Company an extension of the deadline to regain compliance with Nasdaq Listing Rule 5550(b).

30 Dec 2010

FDA stops pain drug trial over safety concerns

Johnson & Johnson revealed Tuesday this week that a clinical trial of its experimental pain drug, fulranumab, has been stopped after the Food and Drug Administration expressed concerns that patients taking the drug could suffer increased joint damage.

29 Dec 2010

Molecular interaction between structural HCV protein and protein critical to viral replication identified

Scientists from the Florida campus of The Scripps Research Institute have identified a molecular interaction between a structural hepatitis C virus protein (HCV) and a protein critical to viral replication. This new finding strongly suggests a novel method of inhibiting the production of the virus and a potential new therapeutic target for hepatitis C drug development.

29 Dec 2010

NEI awards Case Western Reserve $10M for study of retinal diseases

The Departments of Pharmacology and Ophthalmology and Visual Sciences at Case Western Reserve University School of Medicine have been awarded a $10.1 million grant from the National Eye Institute (NEI) to research and develop new treatments for diseases of the retina, a leading cause of blindness.

29 Dec 2010

Patients unresponsive to anti-anemia drug have higher risk of cardiovascular disease, death

Patients with diabetes, kidney disease and anemia who don't respond to treatment with an anti-anemia drug have a higher risk of cardiovascular disease or death, researchers at UT Southwestern Medical Center have found.

28 Dec 2010

Intellect obtains pharmacokinetic data from OX1 Phase 1b trial for Alzheimer's disease

Intellect Neurosciences, Inc., a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has obtained a draft pharmacokinetic report from its completed Phase 1b trial for its lead Alzheimer's candidate, OX1. The Company previously reported on the safety aspects of the trial, which demonstrated that OX1 is safe and well tolerated at all dose levels tested.

28 Dec 2010

Proellex vaginal delivery exhibits four times activity of oral dose in animal study

Repros Therapeutics Inc. today announced it has completed two animal model studies of the use of Proellex® in a vaginally administered formulation that demonstrated effects on progesterone sensitive tissues equivalent to the highest oral dose formerly in development by the Company.

28 Dec 2010

Turns mortal heart attacks into non-mortal heart attacks -- NIH study

Three weeks of oral resveratrol or Longevinex- ingestion prior to an induced heart attack returned microRNA activity close to their pre-event levels in excised animal hearts. Among thousands of microRNA's studied, just six were attributed to exerting the majority of the gene-switching effects measured in the animal heart study - four microRNA optimally regulated by Longevinex- and two optimally by plain resveratrol.

28 Dec 2010

Exiqon announces introduction of GLP compliant services for miRNA biomarker screening

Exiqon A/S, a leading provider of technologies for biomarker detection, today announced the introduction of GLP compliant services for miRNA biomarker screening and diagnostic assay development for clinical trials.

27 Dec 2010

Law expert analyses relationship between modern sport and the law

From match fixing, to doping allegations, to contract disputes, a new book by a Queen's University law expert analyses the relationship between modern sport and the law.

24 Dec 2010

New study shows striking changes, variations by region in admission rates for substance abuse treatment

Although the overall rate of admissions to substance abuse treatment in the U.S. remained stable between 1998 and 2008, at about 770 admissions for every 100,000 persons in the population, a new study shows striking changes and variations in admission rates by region. For example, the rate of admissions for alcohol as the primary drug has declined by 15 percent nationally. However admission rates for alcohol in West North Central states (Ark., Iowa, Kan., Minn., Mo., N.D., Neb. and S.D.) remained the same.

24 Dec 2010

Gold-coated liposomes could make chemotherapy more effective without harmful side effects

University of Arizona researchers may have found a way to deliver chemotherapeutic drugs to cancer tissues in controlled doses without harming healthy body cells.

24 Dec 2010

Drugs News and Research

First whole genome sequence of Parsi breast cancer woman

New ATS guidelines for treating fungal infection in adult pulmonary and critical care patients

Genocea announces close of $35 million Series B venture financing round

General anaesthesia brings reversible coma and not sleep: Study

Immunitor reports positive safety imm01 clinical trial against tuberculosis

Health and Safety Watch tracks over 500 food and product advisories and recalls in 2010

General anesthesia's similarities with and differences from sleep and coma

Neuroscientists say that general anesthesia is a reversible coma

Intellipharmaceutics granted extension of deadline to regain compliance with Nasdaq Listing Rule

FDA stops pain drug trial over safety concerns

Molecular interaction between structural HCV protein and protein critical to viral replication identified

NEI awards Case Western Reserve $10M for study of retinal diseases

Patients unresponsive to anti-anemia drug have higher risk of cardiovascular disease, death

Intellect obtains pharmacokinetic data from OX1 Phase 1b trial for Alzheimer's disease

Proellex vaginal delivery exhibits four times activity of oral dose in animal study

Turns mortal heart attacks into non-mortal heart attacks -- NIH study

Exiqon announces introduction of GLP compliant services for miRNA biomarker screening

Law expert analyses relationship between modern sport and the law

New study shows striking changes, variations by region in admission rates for substance abuse treatment

Gold-coated liposomes could make chemotherapy more effective without harmful side effects

Drug Discovery - Second Edition eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News